DK2017269T3 - Krystallinsk form II af ritonavirindeholdende farmaceutisk sammensætning og fremstilling heraf - Google Patents

Krystallinsk form II af ritonavirindeholdende farmaceutisk sammensætning og fremstilling heraf

Info

Publication number
DK2017269T3
DK2017269T3 DK08007622T DK08007622T DK2017269T3 DK 2017269 T3 DK2017269 T3 DK 2017269T3 DK 08007622 T DK08007622 T DK 08007622T DK 08007622 T DK08007622 T DK 08007622T DK 2017269 T3 DK2017269 T3 DK 2017269T3
Authority
DK
Denmark
Prior art keywords
ritonavir
preparation
pharmaceutical composition
crystalline form
containing pharmaceutical
Prior art date
Application number
DK08007622T
Other languages
English (en)
Inventor
John F Bauer
Azita Saleki-Gerhardt
Sanjay R Chemburkar
Ketan Patel
Harry O Spiwek
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26817251&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2017269(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbott Lab filed Critical Abbott Lab
Application granted granted Critical
Publication of DK2017269T3 publication Critical patent/DK2017269T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/28—Radicals substituted by nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
DK08007622T 1998-07-20 1999-07-19 Krystallinsk form II af ritonavirindeholdende farmaceutisk sammensætning og fremstilling heraf DK2017269T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11934598A 1998-07-20 1998-07-20
US32609399A 1999-06-04 1999-06-04
EP20030029709 EP1418174B1 (en) 1998-07-20 1999-07-19 Amorphous Ritonavir

Publications (1)

Publication Number Publication Date
DK2017269T3 true DK2017269T3 (da) 2012-03-05

Family

ID=26817251

Family Applications (3)

Application Number Title Priority Date Filing Date
DK03029709T DK1418174T3 (da) 1998-07-20 1999-07-19 Amorf ritonavir
DK99934143T DK1097148T3 (da) 1998-07-20 1999-07-19 Ritonavir-polymorf
DK08007622T DK2017269T3 (da) 1998-07-20 1999-07-19 Krystallinsk form II af ritonavirindeholdende farmaceutisk sammensætning og fremstilling heraf

Family Applications Before (2)

Application Number Title Priority Date Filing Date
DK03029709T DK1418174T3 (da) 1998-07-20 1999-07-19 Amorf ritonavir
DK99934143T DK1097148T3 (da) 1998-07-20 1999-07-19 Ritonavir-polymorf

Country Status (29)

Country Link
EP (4) EP2298751A3 (da)
JP (4) JP4815050B2 (da)
KR (3) KR100793046B1 (da)
CN (5) CN1310715B (da)
AR (5) AR019431A1 (da)
AT (3) ATE425974T1 (da)
AU (1) AU768207B2 (da)
BG (4) BG65150B1 (da)
BR (1) BR9912010A (da)
CA (3) CA2337846C (da)
CO (1) CO5090830A1 (da)
CY (2) CY1111600T1 (da)
CZ (2) CZ307116B6 (da)
DE (2) DE69940616D1 (da)
DK (3) DK1418174T3 (da)
ES (3) ES2372990T3 (da)
HU (3) HU229999B1 (da)
ID (1) ID27996A (da)
IL (4) IL140492A0 (da)
MY (2) MY121765A (da)
NO (2) NO318385B1 (da)
NZ (2) NZ522690A (da)
PL (2) PL213978B1 (da)
PT (3) PT1418174E (da)
SI (3) SI1418174T1 (da)
SK (3) SK287586B6 (da)
TR (1) TR200100171T2 (da)
TW (3) TWI227713B (da)
WO (1) WO2000004016A2 (da)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6894171B1 (en) 1998-07-20 2005-05-17 Abbott Laboratories Polymorph of a pharmaceutical
MY121765A (en) * 1998-07-20 2006-02-28 Abbott Lab Polymorph of ritonavir
TR200103488T2 (tr) * 1999-06-04 2002-04-22 Abbott Laboratories Geliştirilmiş farmasötik formülasyonlar.
MXPA03010771A (es) * 2001-05-25 2004-07-01 Abbott Lab Capsulas elasticas blandas que comprenden ritonavir y/o lopinavir.
TWI286476B (en) * 2001-12-12 2007-09-11 Tibotec Pharm Ltd Combination of cytochrome P450 dependent protease inhibitors
US7205413B2 (en) 2002-05-03 2007-04-17 Transform Pharmaceuticals, Inc. Solvates and polymorphs of ritonavir and methods of making and using the same
US8377952B2 (en) * 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
BRPI0401742B8 (pt) 2004-05-13 2021-05-25 Cristalia Produtos Quim Farmaceuticos Ltda composto análogo do ritonavir útil como inibidor de protease retroviral, preparação do composto análogo do ritonavir e composição farmacêutica do composto análogo do ritonavir
US20080312300A1 (en) * 2005-05-30 2008-12-18 Yoginder Pal Sachdeva Processes for the Preparation of Stable Polymorphic Form I of Ritonavir
WO2008041176A2 (en) * 2006-10-03 2008-04-10 Ranbaxy Laboratories Limited Process for the preparation of form i and form ii of ritonavir
CN102898398B (zh) * 2011-07-27 2015-01-14 上海迪赛诺药业有限公司 一种制备i型利托那韦多晶型结晶的方法
ES2587559T3 (es) 2012-03-07 2016-10-25 Ratiopharm Gmbh Forma farmacéutica que comprende lopinavir y ritonavir
HUE027829T2 (en) 2012-03-07 2016-11-28 Ratiopharm Gmbh Dosage forms containing non-crystalline lopinavir and crystalline ritonavir
HK1220390A1 (zh) 2013-08-29 2017-05-05 Teva Pharmaceutical Industries Ltd. 包括恩曲他滨，替诺福韦，达芦那韦和利托那韦的单位剂型以及包含达芦那韦和利托那韦的单体片剂
CA2942877A1 (en) 2014-04-08 2015-10-15 Nitzan SHAHAR Unit dosage form comprising emtricitabine, tenofovir, darunavir and ritonavir
CN106749085B (zh) * 2016-12-23 2019-05-24 东北制药集团股份有限公司 一种制备利托那韦的方法
EP3569225A1 (en) 2018-05-18 2019-11-20 Pharmaceutical Oriented Services Ltd Solid dispersion containing ritonavir
RU2759544C1 (ru) * 2021-01-29 2021-11-15 Общество с ограниченной ответственностью "АМЕДАРТ" Твёрдая фармацевтическая композиция для изготовления перорального терапевтического средства для профилактики и/или лечения ВИЧ-инфекции

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5354866A (en) 1989-05-23 1994-10-11 Abbott Laboratories Retroviral protease inhibiting compounds
US5539122A (en) 1989-05-23 1996-07-23 Abbott Laboratories Retroviral protease inhibiting compounds
CA2170020C (en) * 1992-12-29 2005-08-02 Dale J. Kempf Retroviral protease inhibiting compounds
IL110752A (en) 1993-09-13 2000-07-26 Abbott Lab Liquid semi-solid or solid pharmaceutical composition for an HIV protease inhibitor
US5559158A (en) 1993-10-01 1996-09-24 Abbott Laboratories Pharmaceutical composition
US5491253A (en) 1993-10-22 1996-02-13 Abbott Laboratories Process for the preparation of a substituted 2,5-diamino-3-hydroxyhexane
IL111991A (en) 1994-01-28 2000-07-26 Abbott Lab Liquid pharmaceutical composition of HIV protease inhibitors in organic solvent
US5567823A (en) * 1995-06-06 1996-10-22 Abbott Laboratories Process for the preparation of an HIV protease inhibiting compound
US6037157A (en) 1995-06-29 2000-03-14 Abbott Laboratories Method for improving pharmacokinetics
US6160122A (en) 1996-06-28 2000-12-12 Abbott Laboratories Process for the preparation of a disubstituted thiazole
ZA9710071B (en) 1996-11-21 1998-05-25 Abbott Lab Pharmaceutical composition.
MY121765A (en) * 1998-07-20 2006-02-28 Abbott Lab Polymorph of ritonavir
DE19856432A1 (de) * 1998-12-08 2000-06-15 Basf Ag Nanopartikuläre Kern-Schale Systeme sowie deren Verwendung in pharmazeutischen und kosmetischen Zubereitungen
TR200103488T2 (tr) * 1999-06-04 2002-04-22 Abbott Laboratories Geliştirilmiş farmasötik formülasyonlar.

Also Published As

Publication number Publication date
SK287381B6 (sk) 2010-08-09
CZ307116B6 (cs) 2018-01-24
CY1112139T1 (el) 2015-11-04
DK1418174T3 (da) 2009-05-18
MY145265A (en) 2012-01-13
EP2017269A3 (en) 2009-06-10
KR100853371B1 (ko) 2008-08-22
CZ298188B6 (cs) 2007-07-18
AR019431A1 (es) 2002-02-20
CZ2001203A3 (en) 2001-05-16
AU768207B2 (en) 2003-12-04
MY121765A (en) 2006-02-28
DE69940616D1 (de) 2009-04-30
BG105197A (en) 2001-10-31
BG65963B1 (bg) 2010-07-30
IL140492A (en) 2010-12-30
IL140492A0 (en) 2002-02-10
HU229999B1 (en) 2015-04-28
TW200716550A (en) 2007-05-01
SK286388B6 (sk) 2008-09-05
EP2017269A9 (en) 2009-10-14
EP1097148B1 (en) 2004-03-17
AR059763A2 (es) 2008-04-30
KR100793046B1 (ko) 2008-01-10
TWI271400B (en) 2007-01-21
ID27996A (id) 2001-05-03
CA2337846C (en) 2006-02-21
NO20042393L (no) 2001-01-18
HUP0103823A3 (en) 2003-05-28
AU5003799A (en) 2000-02-07
KR20010072003A (ko) 2001-07-31
TWI227713B (en) 2005-02-11
CN1310715A (zh) 2001-08-29
IL191582A (en) 2016-02-29
KR20060118022A (ko) 2006-11-17
DK1097148T3 (da) 2004-04-26
EP1097148A2 (en) 2001-05-09
HU0800266D0 (en) 2008-06-30
EP2017269A8 (en) 2009-09-30
AR049658A2 (es) 2006-08-23
CA2510949C (en) 2009-11-17
NO327320B1 (no) 2009-06-08
SK287586B6 (sk) 2011-03-04
JP2017061475A (ja) 2017-03-30
EP2298751A3 (en) 2011-08-17
BG109682A (bg) 2007-03-30
EP2017269A2 (en) 2009-01-21
HK1121155A1 (en) 2009-04-17
SK922001A3 (en) 2001-07-10
WO2000004016A2 (en) 2000-01-27
CZ2006533A3 (cs) 2001-05-16
DE69915628D1 (en) 2004-04-22
PL213978B1 (pl) 2013-05-31
TWI362382B (en) 2012-04-21
EP1418174A2 (en) 2004-05-12
CA2674800A1 (en) 2000-01-27
AR059764A2 (es) 2008-04-30
KR100740796B1 (ko) 2007-07-20
ATE534636T1 (de) 2011-12-15
NO20010298L (no) 2001-01-18
CN1310715B (zh) 2010-11-03
KR20040081137A (ko) 2004-09-20
CN101966180A (zh) 2011-02-09
EP2298751A2 (en) 2011-03-23
JP5732212B2 (ja) 2015-06-10
NZ509125A (en) 2003-02-28
JP2010270135A (ja) 2010-12-02
IL191582A0 (en) 2008-12-29
CN1502613A (zh) 2004-06-09
NO318385B1 (no) 2005-03-14
SI2017269T1 (sl) 2012-02-29
HU230150B1 (hu) 2015-09-28
WO2000004016A3 (en) 2000-03-30
IL187181A (en) 2009-09-01
EP1418174B1 (en) 2009-03-18
HUP0103823A2 (hu) 2002-02-28
JP4815050B2 (ja) 2011-11-16
HU227540B1 (en) 2011-08-29
HU0800267D0 (en) 2008-06-30
CN101259128A (zh) 2008-09-10
DE69915628T2 (de) 2004-08-12
NZ522690A (en) 2004-04-30
BG65150B1 (bg) 2007-04-30
ATE261947T1 (de) 2004-04-15
NO20010298D0 (no) 2001-01-18
EP1418174A3 (en) 2004-06-23
JP2002520410A (ja) 2002-07-09
BG110080A (bg) 2008-11-28
JP2014074047A (ja) 2014-04-24
TR200100171T2 (tr) 2001-05-21
ES2322759T3 (es) 2009-06-26
ES2214038T3 (es) 2004-09-01
BR9912010A (pt) 2001-04-10
CO5090830A1 (es) 2001-10-30
ES2372990T3 (es) 2012-01-30
SI1097148T1 (en) 2004-10-31
CY1111600T1 (el) 2015-10-07
HK1037918A1 (en) 2002-02-22
CA2510949A1 (en) 2000-01-27
PL194710B1 (pl) 2007-06-29
IL187181A0 (en) 2008-02-09
SI1418174T1 (sl) 2009-08-31
CN102153524A (zh) 2011-08-17
EP2017269B1 (en) 2011-11-23
AR044029A2 (es) 2005-08-24
BG66140B1 (bg) 2011-07-29
PL348033A1 (en) 2002-05-06
PT2017269E (pt) 2011-12-20
PT1418174E (pt) 2009-06-08
ATE425974T1 (de) 2009-04-15
CA2337846A1 (en) 2000-01-27
PT1097148E (pt) 2004-05-31

Similar Documents

Publication Publication Date Title
DK2017269T3 (da) Krystallinsk form II af ritonavirindeholdende farmaceutisk sammensætning og fremstilling heraf
PT1066027E (pt) Composicao farmaceutica de topiramato
DE69918233D1 (de) Polymilchsäure zusammensetzung und daraus hergestellter film
NO20004741D0 (no) Farmasøytiske blandinger for forlenget peptidfrigjøring og fremstillingsmetode
IS1896B (is) Framleiðsla og kristalform af 2-methýl-thíeno-bensodíasepín
DK1674084T3 (da) Forlænget frigivelse af oral dosissammensætning
EE200200149A (et) Kinasoliinühendid ja neid sisaldavad ravimkoostised
DK1275387T3 (da) Fremgangsmåde til fremstilling af farmaceutiske præparater af fenofibrat med höj biologisk tilgængelighed
DK0980240T3 (da) Sammensætninger med lang frigivelse og fremgangsmåde til fremstilling heraf
IS5747A (is) Oxazólidínón afleiður, aðferð fyrir framleiðslu þeirra og lyfjasamsetninga sem innihalda þær
DK0787745T3 (da) Fremstilling af inulinprodukter
DK0969836T3 (da) Lactosefri, ikke-vandsugende og vandfri farmaceutiske sammensætninger af descarbethoxyloratadin
NO20016173D0 (no) Gipssammensetninger og fremgangsmåter ved fremstilling derav
IS2325B (is) Örgerðar samsetningar epleróns
ID27415A (id) Komposisi farmaseutik
NO20005913L (no) Legemiddelsammensetning
DK0682945T3 (da) Oralt præparat med forsinket frigivelse
DK0991641T3 (da) Krystallinsk form af omeprazol-natriumsalt
IS6508A (is) Lyfjasamsetningar af glycogen fosfórýlasa lötum
DK199900234U4 (da) Paroxetin-methansulfonat i krystallinsk form, farmaceutisk præparat indeholdende dette og andvendelse af forbindelsen til f
NO20003067L (no) Antipicornavirus-forbindelser og fremgangsmÕter for deres anvendelse og fremstilling
ID29262A (id) Komposisi farmasi
PT1014987E (pt) Composicoes orais de levosimendano
EE200200105A (et) Radiofarmatseutilised saadused ja nende valmistamise meetod
DK1121116T3 (da) Farmaceutisk præparat af fluvastatin med opretholdt frigivelse